Sort   by:  
 Page size 
UnknownT cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses.
Not available
S-EPMC8024333 | biostudies-literature
UnknownFatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses.
Not available
S-EPMC9310533 | biostudies-literature
UnknownOmicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.
Not available
S-EPMC8722586 | biostudies-literature
UnknownSARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.
Not available
S-EPMC8723827 | biostudies-literature
UnknownDetection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020.
Not available
S-EPMC7651873 | biostudies-literature
UnknownOverall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
Not available
S-EPMC10207856 | biostudies-literature
UnknownMapping the human genetic architecture of COVID-19.
Not available
S-EPMC8674144 | biostudies-literature
Sort   by:  
 Page size